Search research articles
Contact Us
Filters
Showing results (61-70 of 83) with videos related to
Page
of 9
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
October 23, 2022
Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise
Roselle A Herring, Iain Parsons, Fariba Shojaee-Moradie, et al.
Diabetes
|
April 28, 2005
Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma
Ulf Risérus, Garry D Tan, Barbara A Fielding, et al.
The British Journal of Nutrition
|
September 18, 2003
Long-term monounsaturated fatty acid diets reduce platelet aggregation in healthy young subjects
Ruth D Smith, Colette N M Kelly, Barbara A Fielding, et al.
The American Journal of Clinical Nutrition
|
March 6, 2021
Palmitic acid-rich oils with and without interesterification lower postprandial lipemia and increase atherogenic lipoproteins compared with a MUFA-rich oil: A randomized controlled trial
Charlotte E Mills, Scott V Harding, Mariam Bapir, et al.
Diabetes Care
|
October 17, 2013
Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro
Henrike Sell, Matthias Blüher, Nora Klöting, et al.
Diabetes
|
October 15, 2010
Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition?
Siobhán E McQuaid, Leanne Hodson, Matthew J Neville, et al.
Diabetes Care
|
July 10, 2020
Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes
Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, et al.
Diabetes Care
|
February 20, 2021
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136
Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, et al.
Diabetes Care
|
March 21, 2022
The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes
Roselle A Herring, Fariba Shojaee-Moradie, Mary Stevenage, et al.
The American Journal of Clinical Nutrition
|
August 7, 2024
Variation of LDL cholesterol in response to the replacement of saturated with unsaturated fatty acids: a nonrandomized, sequential dietary intervention; the Reading, Imperial, Surrey, Saturated fat Cholesterol Intervention ("RISSCI"-1) study
Athanasios Koutsos, Bruce A Griffin, Rona Antoni, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 83) with videos related to
Sort By:
Page
of 9
The Journal of Clinical Endocrinology and Metabolism
|
October 23, 2022
Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise
Roselle A Herring, Iain Parsons, Fariba Shojaee-Moradie, et al.
Diabetes
|
April 28, 2005
Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma
Ulf Risérus, Garry D Tan, Barbara A Fielding, et al.
The British Journal of Nutrition
|
September 18, 2003
Long-term monounsaturated fatty acid diets reduce platelet aggregation in healthy young subjects
Ruth D Smith, Colette N M Kelly, Barbara A Fielding, et al.
The American Journal of Clinical Nutrition
|
March 6, 2021
Palmitic acid-rich oils with and without interesterification lower postprandial lipemia and increase atherogenic lipoproteins compared with a MUFA-rich oil: A randomized controlled trial
Charlotte E Mills, Scott V Harding, Mariam Bapir, et al.
Diabetes Care
|
October 17, 2013
Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro
Henrike Sell, Matthias Blüher, Nora Klöting, et al.
Diabetes
|
October 15, 2010
Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition?
Siobhán E McQuaid, Leanne Hodson, Matthew J Neville, et al.
Diabetes Care
|
July 10, 2020
Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes
Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, et al.
Diabetes Care
|
February 20, 2021
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136
Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, et al.
Diabetes Care
|
March 21, 2022
The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes
Roselle A Herring, Fariba Shojaee-Moradie, Mary Stevenage, et al.
The American Journal of Clinical Nutrition
|
August 7, 2024
Variation of LDL cholesterol in response to the replacement of saturated with unsaturated fatty acids: a nonrandomized, sequential dietary intervention; the Reading, Imperial, Surrey, Saturated fat Cholesterol Intervention ("RISSCI"-1) study
Athanasios Koutsos, Bruce A Griffin, Rona Antoni, et al.
Page
of 9